Company / Return on Equity (ROE)
Century Therapeutics, Inc. Return on Equity (ROE) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-78.4%
FY2025
5-year range
-78.4% / -24.2%
FY2022-FY2025
Trend
-6.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Century Therapeutics, Inc. reports negative total equity of -78.4% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-78.4% in FY2025 with a 3-year CAGR of -54.3%.
Declined from -43.3% to -78.4% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -54.3pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- Century Therapeutics, Inc.'s return on equity (roe) has declined for 3 consecutive years.
- In FY2025, return on equity (roe) decreased 6.0% year-over-year.
Company context
Key Data Points
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -78.4% | -6.0% |
| FY2024 | -74.0% | -71.1% |
| FY2023 | -43.3% | -78.9% |
| FY2022 | -24.2% | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026